Skip to Content
Merck
All Photos(1)

Key Documents

419656

Sigma-Aldrich

N-Benzyl-2-nitro-1H-imidazole-1-acetamide

97%

Synonym(s):

2-Nitro-N-(phenylmethyl)-1H-imidazole-1-acetamide, Benzonidazol, N-Benzyl-2-nitroimidazol-1-yl-acetamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H12N4O3
CAS Number:
Molecular Weight:
260.25
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.22

Assay

97%

mp

189-192 °C (lit.)

solubility

methanol: soluble 50 mg/mL, clear, colorless to yellow

functional group

amide
nitro
phenyl

SMILES string

[O-][N+](=O)c1nccn1CC(=O)NCc2ccccc2

InChI

1S/C12H12N4O3/c17-11(14-8-10-4-2-1-3-5-10)9-15-7-6-13-12(15)16(18)19/h1-7H,8-9H2,(H,14,17)

InChI key

CULUWZNBISUWAS-UHFFFAOYSA-N

General description

N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) is a nitro-heterocyclic compound. It is widely employed drug for the treatment of Chagas disease. It exhibits three polymorphic forms..

Application

N-Benzyl-2-nitro-1H-imidazole-1-acetamide (Benznidazole) may be used as reference drug for the extraction of guaianolide from the aerial parts of Tanacetum parthenium and to evaluate its in vitro antiprotozoal activity.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

D E Perez-Mazliah et al.
The Journal of antimicrobial chemotherapy, 68(2), 424-437 (2012-10-30)
Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed. Herein, a pilot study was conducted to evaluate
Israel Molina et al.
The New England journal of medicine, 370(20), 1899-1908 (2014-05-16)
Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtimox, which have been associated with low cure rates in the chronic stage of the disease and which have considerable toxicity. Posaconazole has shown trypanocidal activity in murine models.
Glaucia Vilar-Pereira et al.
Brain, behavior, and immunity, 26(7), 1136-1149 (2012-07-31)
Inflammatory cytokines and microbe-borne immunostimulators have emerged as triggers of depressive behavior. Behavioral alterations affect patients chronically infected by the parasite Trypanosoma cruzi. We have previously shown that C3H/He mice present acute phase-restricted meningoencephalitis with persistent central nervous system (CNS)
Alejandra B Ciccarelli et al.
Antimicrobial agents and chemotherapy, 56(10), 5315-5320 (2012-08-08)
A nutritional characteristic of trypanosomatid protozoa is that they need a heme compound as a growth factor. Because of the cytotoxic activity of heme and its structural similarity to cobalamins, we have investigated the in vitro and in vivo effect
Jean-Philippe Chippaux et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene, 107(1), 1-7 (2013-01-09)
A randomised, unblinded, clinical trial comparing two benznidazole regimens for congenital Chagas disease was carried out to determine whether simplification and reduction in the length of treatment could lead to better treatment compliance. This study was conducted in Santa Cruz

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service